Candiduria – mycolab.ai

Prevalence and antifungal susceptibility profiles of Candida isolates among patients with candiduria: a multiplex PCR assay

mycolabadmin

Researchers studied urinary tract infections caused by yeast (Candida species) in hospitalized patients. Using advanced molecular testing, they found that while the common yeast Candida albicans was most prevalent, other yeast species were increasingly showing resistance to antifungal medications, particularly to fluconazole. The study highlights the importance of identifying which specific yeast species is causing an infection to choose the most effective treatment.

Prevalence and antifungal susceptibility profiles of Candida isolates among patients with candiduria: a multiplex PCR assay

mycolabadmin

This study examined Candida yeast infections in urine samples from hospitalized patients in Iran. Researchers identified seven different Candida species using a specialized PCR test and tested how well they responded to three antifungal medications. They found that while Candida albicans was most common, other species showed much higher resistance to fluconazole treatment. The findings highlight the importance of proper species identification for choosing the right treatment.

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

Researchers in Iran studied 136 hospital patients to identify different types of Candida fungal infections using a molecular laboratory technique called PCR-RFLP. They found that while Candida albicans remained the most common species, other Candida species were increasingly prevalent in hospitalized patients. The study developed a cost-effective diagnostic method that could help developing countries identify these fungal infections faster and more accurately, though the dangerous multidrug-resistant Candida auris was not found in their samples.

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

This study evaluated a simple molecular test called PCR-RFLP to identify different types of Candida fungi in hospitalized patients in Iran. Among 136 patient samples, researchers found eight different Candida species, with common Candida albicans being most prevalent, but other more dangerous species also present. No cases of the emerging pathogen Candida auris were found, though the test method can effectively detect it. The researchers conclude this cost-effective test could be valuable for identifying dangerous fungal infections in developing countries.

Prevalence and antifungal susceptibility profiles of Candida isolates among patients with candiduria: a multiplex PCR assay

mycolabadmin

Researchers studied fungal infections in urine samples from hospitalized patients and found that while the common yeast Candida albicans was most prevalent, other Candida species were increasingly resistant to antifungal medications. Using advanced genetic testing methods, they identified seven different Candida species and tested their resistance to three common antifungal drugs. The findings highlight the growing problem of drug-resistant fungal infections and the need for better diagnostic tools to identify which species is causing infection so appropriate treatment can be selected.

Epidemiology of Candidemia, Candiduria and Emerging Candidozyma (Candida) auris Across Gulf Cooperative Council Countries and Yemen in the Arabian Peninsula

mycolabadmin

This comprehensive review examines fungal bloodstream and urinary tract infections caused by Candida species across Middle Eastern countries. The study shows that while Candida albicans remains common, dangerous antibiotic-resistant strains like Candidozyma auris are increasingly appearing in hospitals. The research highlights that better diagnostic tools and infection prevention practices are urgently needed in the region to protect patients and reduce deaths from these serious infections.

Prevalence and antifungal susceptibility profiles of Candida isolates among patients with candiduria: a multiplex PCR assay

mycolabadmin

Researchers studied yeast infections in urine from hospitalized patients using advanced molecular testing. They found that while Candida albicans was most common, other yeast species were becoming more resistant to antifungal medications. The study used a 21-tube PCR test to identify different yeast species and tested which medications worked best against them. Results showed that newer yeast species were much more likely to resist commonly used antifungal drugs like fluconazole.

The efficacy of luliconazole and caspofungin on planktonic and biofilm of Candida albicans from different sources

mycolabadmin

Candida albicans, a common yeast infection organism, can form tough protective structures called biofilms that resist antifungal medications. This study tested two antifungal drugs (luliconazole and caspofungin) against Candida in both regular form and biofilm form. The results showed that while these drugs work well against regular Candida cells, they are much less effective against biofilms, which require 15-171 times higher doses to be inhibited. The strongest biofilms came from vaginal infections, suggesting that different infection types may require different treatment approaches.

Trichosporon Urinary Tract Infections: A Hidden Menace Revealed

mycolabadmin

Trichosporon is a fungus that causes urinary tract infections primarily in hospitalized patients and those with weakened immune systems. This review found that Trichosporon asahii is the most common species responsible for these infections, especially in patients with prolonged hospital stays or using immunosuppressive medications. The drug voriconazole works best against this fungus, while some common antifungal medications like amphotericin B are less effective. Accurate identification using modern laboratory techniques is crucial for proper treatment.

Renaming Candida glabrata—A case of taxonomic purity over clinical and public health pragmatism

mycolabadmin

Candida glabrata is a common yeast infection that causes serious illnesses in humans, affecting millions of people worldwide. Scientists have recently proposed renaming it to Nakaseomyces glabrata for technical taxonomic reasons. However, this article argues against the change because it would create confusion for doctors, complicate treatment instructions on medications, disrupt disease tracking systems, and make it harder for patients to understand their conditions. Keeping the familiar name Candida glabrata is more practical and helpful for patient care and public health than strict adherence to taxonomic classification rules.

Disease: Candiduria